Chimeric flavivirus vaccines
AssigneesAcambis Inc., St. Louis University
InventorsThomas J. Chambers, Thomas P. Monath, Farshad Guirakhoo, Juan Arroyo
Life of this patent
Estimating the term…
Abstract
A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.
Claims14
A chimeric live, infectious, attenuated virus, comprising:
- a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow fever virus prM-E protein is not expressed, and
- integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, to that said prM-E protein of said second flavivirus is expressed, wherein the capsid protein of said chimeric virus is from yellow fever virus.
A method of preventing or treating Japanese encephalitis virus infection in a patient, said method comprising administering to said patient a chimeric, live, infectious, attenuated virus comprising:
- a yellow fever virus in which the nucleotide sequence encoding a prM-E protein is either deleted, truncated, or mutated so that functional yellow fever virus prM-E protein is not expressed, and
- integrated into the genome of said yellow fever virus, a nucleotide sequence encoding a prM-E protein of Japanese encephalitis virus strain SA-14-14-2 or Japanese encephalitis virus strain Nakayama, wherein the capsid protein of said chimeric virus is from yellow fever virus.
Dependencies are inferred from the claim text.